Q-omics provides the consensus-scored CNGA4 profile across patient tissues and cancer cell-line models. CNGA4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNGA4 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, CNGA4 RNA expression shows 17,156 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where CNGA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNGA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNGA4 survival associations across molecular data types. CNGA4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNGA4 RNA expression–survival associations across cancer types. High CNGA4 expression shows unfavorable associations in KIRC, COAD and LIHC, but favorable associations in SARC, BRCA and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNGA4 RNA expression.
This table summarizes CNGA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CNGA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNGA4 shows lower tumor expression in LUAD, KICH, LUSC, THCA and BLCA and higher tumor expression in CHOL. The LUAD box plot shows higher CNGA4 RNA expression in normal versus tumor tissue (log2 FC = −1.283, t-test p < 0.001).
This table shows molecular features associated with CNGA4 in patient tissues and cancer cell lines. In patient samples, CNGA4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CNGA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
